How to Check QLine Biotech IPO Allotment Status

Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing, and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs.

The company supplies diagnostic equipment and IVD products directly or through distributors, majorly to diagnostic service providers, hospitals, and medical colleges. Its key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others including POC Devices & Rapid Tests) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices.

As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/ELISA) and 1,200 Selectra Machines. As of March 31, 2026, the manufacturing teams include 126 employees and 223 third-party workers collaborating with R&D, supply chain, and external partners.

Q-Line Biotec IPO is a book build issue of ₹214.48 crore, entirely comprising a fresh issue of 0.63 crore shares aggregating to ₹214.48 crore. The IPO opened on May 21, 2026, and closed on May 25, 2026. The allotment is expected on Tuesday, May 26, 2026. The share price band was set at ₹326 to ₹343 per share.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check QLine Biotech IPO Allotment Status on Registrar Site

• Visit the Purva Sharegistry (India) Pvt. Ltd.
• Select "QLine Biotech" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check QLine Biotech IPO Allotment Status on NSE

• Navigate to the NSE SME IPO Allotment Status Page
• Select the issue type: equity/debt
• Choose "QLine Biotech" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Q-Line Biotec IPO subscribed 102.42 times overall. Here is the category-wise breakdown as of 5:10:00 PM on May 25, 2026::

QLine Biotech IPO Subscription Status

• QIB Category (Ex Anchor): 123.94 times
• Non-Institutional Investors (NII): 145.98 times
• Individual Investors: 71.44 times

Q-Line Biotec IPO Share Price and Investment Details

The minimum investment required was ₹2,74,400 for 2 lots (800 shares) for individual investors. The issue raised ₹61.10 crore from anchor investors. The issue includes a reservation of up to 3,13,200 shares for the market maker, Hem Finlease Pvt. Ltd. The anchor investor lock-in period ends on June 25, 2026 for 50% of shares (30 days) and August 24, 2026 for the remaining shares (90 days). Given the overall subscription of 102.42 times with exceptional institutional interest at 123.94 times, robust NII participation at 145.98 times, and strong individual investor subscription at 71.44 times, the share price listing expectations remain highly positive.

Utilisation of IPO Proceeds

The proceeds will be utilised for meeting working capital requirements (₹93.50 crore), repayment of certain borrowings availed by the Company, in part or full (₹90.00 crore), and general corporate purposes.

Business Overview

Q-Line Biotech Limited is engaged in the business of developing, manufacturing, and marketing of a diverse range of reagents and consumables. The company posted growth in its top lines for the reported periods, but suffered a setback in FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract a fancy price for its IPO.

The company demonstrated financial performance with total income of ₹322.58 crore for FY2025 and a net worth of ₹229.16 crore as of December 31, 2025. The company benefits from established manufacturing capabilities with a focus on R&D, reverse engineering and quality control, a diversified product portfolio with focus on the IVD industry, a widespread distribution network with a presence across all four regions, long-standing relationships with customers, and an experienced promoter and management team. However, investors should note the post-issue P/E ratio of 15.51 and Price to Book Value of 2.44.

Check the latest IPO allotment status to stay informed.